Do Observational Studies Agree With Randomized Trials?: Evaluation of Oral Anticoagulants in Atrial Fibrillation.
作者信息
Siontis Konstantinos C, Checkole Saron, Yao Xiaoxi, Gersh Bernard J, Noseworthy Peter A
出版信息
J Am Coll Cardiol. 2020 Feb 11;75(5):562-563. doi: 10.1016/j.jacc.2019.12.007.
Abstract
摘要
相似文献
1
Do Observational Studies Agree With Randomized Trials?: Evaluation of Oral Anticoagulants in Atrial Fibrillation.观察性研究与随机试验结果一致吗？：心房颤动中口服抗凝剂的评估
J Am Coll Cardiol. 2020 Feb 11;75(5):562-563. doi: 10.1016/j.jacc.2019.12.007.
2
Anticoagulation for atrial fibrillation: underuse?心房颤动的抗凝治疗：使用不足？
Am J Med. 2011 Jul;124(7):e11; author reply e13. doi: 10.1016/j.amjmed.2010.07.030.
3
Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice.为非瓣膜性心房颤动患者选择合适的非维生素 K 拮抗剂口服抗凝剂：基于证据的选择。
Ann Med. 2018 Jun;50(4):288-302. doi: 10.1080/07853890.2018.1460489. Epub 2018 Apr 15.
4
Quality of anticoagulation control in atrial fibrillation.心房颤动抗凝控制的质量
Lancet. 2010 Sep 18;376(9745):935-7. doi: 10.1016/S0140-6736(10)61305-0.
5
Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.非维生素K拮抗剂口服抗凝药与抗血小板治疗预防心房颤动患者卒中：一项随机对照试验的荟萃分析
Cardiol Rev. 2016 Sep-Oct;24(5):218-23. doi: 10.1097/CRD.0000000000000088.
6
Stroke prevention in atrial fibrillation – latest guideline recommendations and real world data.心房颤动的卒中预防——最新指南建议及真实世界数据
Med Monatsschr Pharm. 2017 Apr;40(4):167-70.
7
[Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].[希美加群用于心房颤动的抗栓治疗：它能替代华法林吗？]
Anadolu Kardiyol Derg. 2007 Mar;7(1):54-8.
8
Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis.阵发性心房颤动、中风风险与血栓预防
Thromb Haemost. 2008 Jul;100(1):11-3. doi: 10.1160/TH08-05-0331.
9
The need for new oral anticoagulants in clinical practice.临床实践中对新型口服抗凝剂的需求。
J Cardiovasc Med (Hagerstown). 2009 Aug;10(8):605-9. doi: 10.2459/JCM.0b013e32832e4954.
10
[Risk of thromboembolism in atrial fibrillation].
Orv Hetil. 2016 Sep;157(38):1511-5. doi: 10.1556/650.2016.30575.
引用本文的文献
1
To treat or not to treat: a comparative effectiveness analysis of oral anticoagulant outcomes among U.S. nursing home residents with atrial fibrillation.治疗还是不治疗：美国养老院房颤患者口服抗凝治疗结局的比较效果分析。
BMC Geriatr. 2024 Jul 19;24(1):619. doi: 10.1186/s12877-024-05186-9.
2
Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands.荷兰新发非瓣膜性心房颤动患者特征、抗凝治疗和预后的时间趋势。
JAMA Netw Open. 2023 Apr 3;6(4):e239973. doi: 10.1001/jamanetworkopen.2023.9973.
3
On-treatment follow-up in real-world studies of direct oral anticoagulants in atrial fibrillation: Association with treatment effects.心房颤动直接口服抗凝剂真实世界研究中的治疗期随访：与治疗效果的关联
Int J Cardiol Heart Vasc. 2022 Apr 4;40:101024. doi: 10.1016/j.ijcha.2022.101024. eCollection 2022 Jun.
4
Clinical Efficacy and Safety of Lacosamide as an Adjunctive Treatment in Adults With Refractory Epilepsy.拉科酰胺作为难治性癫痫成人辅助治疗的临床疗效和安全性
Front Neurol. 2021 Dec 3;12:712717. doi: 10.3389/fneur.2021.712717. eCollection 2021.
5
Reappraisal of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis.心房颤动患者非维生素K拮抗剂口服抗凝药的重新评估：一项系统评价和荟萃分析。
Front Cardiovasc Med. 2021 Oct 15;8:757188. doi: 10.3389/fcvm.2021.757188. eCollection 2021.
本文引用的文献
1
Apixaban versus warfarin in patients with atrial fibrillation.阿哌沙班与华法林用于房颤患者。
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
2
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
3
Dabigatran versus warfarin in patients with atrial fibrillation.达比加群与华法林用于房颤患者的比较。
N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
Zotero 插件